XClose

UCL Queen Square Institute of Neurology

Home
Menu

New insights into how immune cells behave in Motor Neuron Disease

2 December 2022

With thanks to the Motor Neurone Disease Association who interviewed Professor Andrea Malaspina and Dr Ozlem Yildiz about their research.

laboratory

 

Yildiz Ozlem
 A recent paper published in the Journal Neurology: Neuroimmunology & Neuroinflammation has revealed new insights into how immune cells behave in MND. This work, which is the result of a collaboration between researchers across different universities, aimed to uncover more about the role of the immune system in MND progression.

The study used blood samples and information collected from people with MND as part of other research projects, such as AMBRoSIA, funded by the MND Association, and the ALS biomarkers study. This data was used to observe the behaviour of immune cells in MND and investigate if it could be related to disease progression. We chatted to Professor Andrea Malaspina and Dr Ozlem Yildiz about this work and what it means to people with MND.

Image: Yildiz Ozlem

AMBRoSIA

A Multicentre Biomarker Resource Strategy In ALS is a 5-year biobanking programme which aims to gather biological and genetic samples from several hundred people living with MND, as well as from donors without the disease, in the UK. This resource has already helped to identify and provide evidence for potential biomarkers (biological fingerprints) of MND, including neurofilament light chain.

ALS Biomarkers study

This study aims to collect biological samples, also remotely, from people with MND, donors without MND and people with other neurological conditions. This ten-year biobanking effort has contributed to some of most important discoveries in the field of biomarkers in ALS, including the role of neurofilaments and immune response in the disease progression.

What did this work focus on?

It is thought that changes occur in the immune system during the course of the disease and that immune cells may transform from being neuroprotective to being neurotoxic. Alterations in the behaviour of cells of the immune system have been suggested to contribute to disease progression and survival.

In this study, we analysed samples from people with slow and fast progressing MND separately. We looked at specific types of immune cells with a focus on cells that change with ageing to see how these changes might contribute to the disease. Symptoms of MND usually appear after the age of 50 and that is why ageing is thought to play a significant role in the disease. We also observe that the older the age of onset, the more rapid the disease progression and this may be due to the fact that as cells age, they may lose their function or start to function abnormally.

What did you find in this research?

We have shown that in people living with MND, there is a higher number of specific B and T lymphocytes showing features of senescence similar to what has been previously observed during the ageing process and in viral infections. We also found that higher amounts of these cells in the blood is linked to a worse prognosis of the disease. This suggests that changes in the immune system might be involved in the development and progression of MND.

There has also been another paper published by a group of American researchers which has shown similar findings in a type of genetic MND using animal models of the disease. This study underlines our findings and helps to provide further evidence that the immune system seems to play a role in motor neuron damage in MND.

What does this mean for people living with MND?

Our research has helped to highlight that there are several factors involved in motor neuron death in MND. It was previously thought that cell death was due to altered behaviour of certain proteins that become toxic in the disease, but this study has increased evidence that the immune system also contributes to motor neuron damage and death. It has been suggested that these faulty proteins may trigger a response from the immune system which is excessive and could harm surrounding neurons. A successful therapy may be about targeting these toxic proteins and the immune response they generate. Bringing immune cells out of this unhealthy, potentially damaging senescent state may be a part of this strategy.  

What are the next steps for this work?

Although the study has helped to identify one of the immune changes that appears to be involved in MND, more studies are needed to uncover more about the immune cells that play a key role in MND and further understand the changes that occur. Further research in this area may help to increase our understanding of the mechanisms behind the disease which could lead to the identification of new biomarkers and potential therapeutic targets.

We wish to thank Andrea and Ozlem for taking the time to talk to us about this research.

Links

Source: